MedTrace Logo

Observational Prospective Study OPTIMA II - Follow-up

NCT02099565 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 572

Last updated 2016-02-25

No results posted yet for this study

Summary

The current follow-up study was planned to reveal the rates of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) during 4-year follow-up in patients participated in OPTIMA study. In addition, the long-term effects of statins on LDL-cholesterol and different biomarkers in patients after drug-eluting stents implantation will be assessed. In addition, such project implementation will allow to clarify the treatment options used by Russian patients with CAD (Coronary Artery Disease) after drug-eluting stent implantation. The information received in this study will help to optimize management of Russian patients with CAD after PCI in order to improve prognosis and quality of life of these patients.

Conditions

  • Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

Sponsors & Collaborators

Principal Investigators

  • Karin Otter, PHD, MD · AstraZeneca

  • Yuri Karpov · Russian Cardiology Research and Production Complex

Eligibility

Min Age
18 Years
Max Age
150 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02099565 on ClinicalTrials.gov